Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 First-in-human Study of BMS-986500 in Advanced Solid Tumors and CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer
jRCT2031250791Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of BMS-986500 in Nonhematologic neoplasms, breast cancer and ovarian cancer (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Dose Limiting Toxicities (DLTs), Number of Participants With Adverse Events (AEs) and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
BMS-986500
03
Conditions
Nonhematologic neoplasmsbreast cancerovarian cancer
Beyond the preview
Go deeper on jRCT2031250791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250791.